-
Mashup Score: 2Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis - 8 month(s) ago
Severe asthma is complex; comorbidities may influence disease outcomes.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0VIDEO: Mepolizumab for EoE does not yield ‘prominent symptom improvement’ after 6 months - 12 month(s) ago
CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 months in patients with eosinophilic esophagitis.“This study came about because of the need for additional treatments for EoE,” Dellon, professor of medicine and director of the Center for
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from #DDW23: #Mepolizumab for #EoE does not yield ‘prominent symptom improvement’ after 6 months @DDWMeeting https://t.co/uoZwiYJYOt
-
-
Mashup Score: 0
Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new study finds that #dupilumab may be more effective than #omalizumab and #mepolizumab in reducing asthma-related exacerbations and improving lung function. Read now! https://t.co/Cq1ZsH1Bfl https://t.co/WqaGT272dV
-
-
Mashup Score: 0Switch patterns in a cohort of individuals with asthma who received omalizumab or mepolizumab therapy - 1 year(s) ago
As more monoclonal antibodies become approved for the treatment of asthma and given that many individuals will be eligible for multiple biologics,1,2 there are ample opportunities to switch between biologics. Switching may reflect the lack of effectiveness and/or poor tolerability of the initial biologic. We evaluated the all-cause switch patterns of omalizumab and mepolizumab as an indicator of…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In current issue! Switch patterns in a #cohort of individuals with #asthma who received #omalizumab or #mepolizumab #therapy https://t.co/0PUGPEytdB https://t.co/uG6Wk2OSZd
-
-
Mashup Score: 1Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma - 1 year(s) ago
Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities are needed to inform clinical practice.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Comorbidities Modify the #Phenotype but Not the #Treatment Effectiveness to #Mepolizumab in Severe #Eosinophilic #Asthma https://t.co/V9m0CcrWyJ https://t.co/bO7wuiI0Rx
-
-
Mashup Score: 1
SAN ANTONIO — Seventy percent of patients with severe eosinophilic asthma on mepolizumab for 5 to 6 years had no exacerbations for 1 year, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Our 70% response rate of ‘super-responders’ is based on monthly exams in general while receiving mepolizumab with monthly Asthma
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
ICYMI: 70% percent of patients with severe eosinophilic #asthma on #mepolizumab for 5 to 6 years had no exacerbations for 1 year, according to data presented at the AAAAI 2023 Annual Meeting. https://t.co/PLrVcMUBgP
-
-
Mashup Score: 0
Asthma is a common chronic respiratory disorder associated with significant disease and economic burden. Mepolizumab is an anti-IL-5 mAb approved for use as an add-on treatment in patients with severe eosinophilic asthma.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! Impact of #Mepolizumab on #Exacerbations in the #US #Medicare #Population https://t.co/F3Wp1w69gB https://t.co/0oPy7zYuY5
-
-
Mashup Score: 0Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma - 1 year(s) ago
Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities is needed to inform clinical practice.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Comorbidities modify the #phenotype but not the #treatment effectiveness to #mepolizumab in severe #eosinophilic #asthma https://t.co/V9m0CcrWyJ
-
-
Mashup Score: 0Partial suppression of type 2 inflammation with mepolizumab - 1 year(s) ago
We read with interest the results of the MAPLE trial showing additional suppression by prednisolone of FeNO, blood, and sputum eosinophils in patients taking mepolizumab.1 These findings illustrate the limited impact of mepolizumab on type 2 inflammation with regard to persistent IL4/IL13 escape in the presence of IL5 blockade.2 As such, this reinforces the importance of carefully observing type…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue (Free)! #Partial #suppression of #type2 #inflammation with #mepolizumab https://t.co/KT54XB5Dl8
-
-
Mashup Score: 0Switch patterns in a cohort of individuals with asthma who received omalizumab or mepolizumab therapy - 1 year(s) ago
Ayobami Akenroye, MBChB MPH PhD Ayobami AkenroyeCorrespondenceCorrespondence: Ayobami Akenroye, MBChB MPH PhD, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, 60 Fenwood Road, Boston, MA 02115 Phone: 617.525.1300AffiliationsDivision of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MAChanning Division of Network Medicine, Brigham and Women’s…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! Switch patterns in a cohort of individuals with #asthma who received #omalizumab or #mepolizumab #therapy https://t.co/0PUGPEytdB
-
In Press! #Mepolizumab in #Patients With #Severe #Asthma and #Comorbidities: 1-Year REALITI-A #Analysis https://t.co/IYMcpQMQXo https://t.co/C6joSyZrJA